Company intelligence / Profile preview
Shouyao Holdings
Beijing, Chinashouyaoholding.com ↗
- Ownership
- Private
- Employees
- ~178
- Development stage
- Other
01
Overview
Shouyao Holdings is a publicly traded Chinese biotech company focused on the research and development of innovative small molecule drugs, primarily targeting oncology and metabolic diseases. Its lead programs include ALK inhibitors and other targeted therapies in late-stage clinical trials for various cancers including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, as well as type II diabetes[2][6]. The company has multiple assets in clinical development with at least one program reaching Phase 3 trials[6].
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Small moleculeProteolysis-targeting chimera therapy
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
PharmaBlock Sciences
Beyond the preview
Go deeper on Shouyao Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shouyao Holdings.